https://www.pharmaradar360.com/article/17f2beca3d6f8d39PharmaRadar360en2026-04-30T11:11:16.000ZGuidance: The Innovative Devices Access Pathway (IDAP)https://www.pharmaradar360.com/article/d59e85130c40e57aPharmaRadar360en2026-04-30T10:59:00.000ZBristol Myers Squibb Reports First Quarter Financial Results for 2026https://www.pharmaradar360.com/article/729dd889872f19d0PharmaRadar360en2026-04-30T10:45:00.000ZLilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicineshttps://www.pharmaradar360.com/article/ddf8746bbee3b801PharmaRadar360en2026-04-30T10:30:00.000ZMerck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestoneshttps://www.pharmaradar360.com/article/2aab7fb7ed9b4597PharmaRadar360en2026-04-30T08:42:11.000ZMEDIA – Press release (on “il Sole 24 Ore”) – 2025 final payment dividendhttps://www.pharmaradar360.com/article/e282f0aedb8bad55PharmaRadar360en2026-04-30T07:39:25.000ZSixth resumed meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement: PABS instrumenthttps://www.pharmaradar360.com/article/6f64aa10fbae4a6cPharmaRadar360en2026-04-30T05:00:00.000ZRoche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026https://www.pharmaradar360.com/article/4d61cea512104ec7PharmaRadar360en2026-04-30T02:00:00.000ZOtsuka Launches "Educational Materials and Resources by Otsuka" for Educators to Support Health Education in Schools Providing Free Digital Health Education Materials on Heat Illness Prevention and Nutrition Educationhttps://www.pharmaradar360.com/article/351d9dd1c49762bbPharmaRadar360en2026-04-30T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/61ecfd05ec11019bPharmaRadar360en2026-04-30T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/c26f9db395bbebbePharmaRadar360en2026-04-30T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/b6316fdc16254520PharmaRadar360en2026-04-30T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/caeedd1b7eb43a8aPharmaRadar360en2026-04-30T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/34c9f3ed439eaca5PharmaRadar360en2026-04-30T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/0a41959ca12c18e2PharmaRadar360en2026-04-30T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/8171619070bba71dPharmaRadar360en2026-04-30T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/9744a54588eb0292PharmaRadar360en2026-04-30T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/b1341d1f8ad70a62PharmaRadar360en2026-04-30T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/6519ad514dd3092fPharmaRadar360en2026-04-30T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/63267a87c1dfaa44PharmaRadar360en2026-04-30T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/131e67196cf6b194PharmaRadar360en2026-04-30T00:00:00.000Z6203https://www.pharmaradar360.com/article/3c02ec606de6e284PharmaRadar360en2026-04-30T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/587927555cb7bb87PharmaRadar360en2026-04-29T20:54:52.000ZNote to Industry on Requirement for Bioequivalence Studyhttps://www.pharmaradar360.com/article/33fd7b95c06f9037PharmaRadar360en2026-04-29T19:39:03.000ZInterfarma na Imprensa: Interfarma ressalta importância de previsibilidade regulatória após adiamento da Resolução CMED nº 3/2025https://www.pharmaradar360.com/article/e68c4522b72d4809PharmaRadar360en2026-04-29T18:09:37.000ZInterfarma destaca papel do acesso sustentável à inovação na edição especial do Global Forum 2026https://www.pharmaradar360.com/article/c1cd26cd30c8c985PharmaRadar360en2026-04-29T17:25:52.000ZInterfarma e Correio realizam Summit Propriedade Intelectual na Agenda Pública; confira a agendahttps://www.pharmaradar360.com/article/cd533ae407ab757bPharmaRadar360en2026-04-29T15:27:36.000ZDefining Leadership for Oneself is Key to Becoming a Leader, ACRP 2026 Panelists Sayhttps://www.pharmaradar360.com/article/b84287601b677ff1PharmaRadar360en2026-04-29T15:22:08.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/9b31696c7bd8a84aPharmaRadar360en2026-04-29T14:41:48.000ZAttendees Encouraged to “Act with Courage, Driven by Purpose” as ACRP 2026 Closeshttps://www.pharmaradar360.com/article/b6ff9984e239ebe8PharmaRadar360en2026-04-29T14:00:27.000ZLa AEMPS informa del cese de comercialización y la retirada del mercado de Deliplus Men Depil bajo la duchahttps://www.pharmaradar360.com/article/17858675018b374aPharmaRadar360en2026-04-29T13:25:56.000ZProrrogação da entrada em vigor da Resolução CMED nº 3/2025 é positiva, avalia Interfarmahttps://www.pharmaradar360.com/article/221b7ac047122b9fPharmaRadar360en2026-04-29T13:18:20.000ZU.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEAhttps://www.pharmaradar360.com/article/7d42b66c47ca7e01PharmaRadar360en2026-04-29T13:07:21.000ZAdial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045https://www.pharmaradar360.com/article/33e66397702016cdPharmaRadar360en2026-04-29T13:02:41.000ZMHRA Safety Roundup: April 2026https://www.pharmaradar360.com/article/a0fec1f12c16641ePharmaRadar360en2026-04-29T13:01:48.000ZGood laboratory practice (GLP) for safety tests on chemicalshttps://www.pharmaradar360.com/article/a08e8c2aee420fd2PharmaRadar360en2026-04-29T13:00:00.000ZCodexis to share RNA manufacturing advances at TIDES USAhttps://www.pharmaradar360.com/article/f45a51d21236ab0aPharmaRadar360en2026-04-29T12:09:15.000ZANMAT cancela la habilitación de la firma REHUE S.A. y prohíbe la comercialización de sus productoshttps://www.pharmaradar360.com/article/1ed9416c1cb05fe1PharmaRadar360en2026-04-29T11:57:18.000ZANMAT suspendió el certificado de buenas prácticas de la firma ELECTRON PLAST S.A. y prohibió la comercialización de productos de terceros con destino a tránsito interjurisdiccionalhttps://www.pharmaradar360.com/article/c3e622490ce8d06aPharmaRadar360en2026-04-29T11:47:00.000ZAbbVie Reports First-Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/f8e0df31f36a72adPharmaRadar360en2026-04-29T10:54:31.000ZRECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2025 FINANCIAL STATEMENTS AND THE DIVIDEND OF €1.34 PER SHARE (+5.5% VS. 2024). NEW BOARD OF STATUTORY AUDITORS APPOINTEDhttps://www.pharmaradar360.com/article/e1c49476af887566PharmaRadar360en2026-04-29T10:22:59.000ZΑνακοίνωση σχετικά με την Ευρωπαϊκή Βάση Δεδομένων Ι/Π- EUDAMEDhttps://www.pharmaradar360.com/article/a0a3a5ce618a8d23PharmaRadar360en2026-04-29T08:46:13.000ZAπαγόρευση διάθεσης και διακίνησης των προϊόντωνhttps://www.pharmaradar360.com/article/2890daf5592b3bf8PharmaRadar360en2026-04-29T08:20:07.000ZEκτέλεση προϋπολογισμού μηνός Μαρτίου 2026https://www.pharmaradar360.com/article/2a431f0de2bbc8daPharmaRadar360en2026-04-29T06:34:07.000ZLa AEMPS adecúa los formatos de antibióticos para alinearlos con las pautas clínicas habituales y evitar su uso inapropiadohttps://www.pharmaradar360.com/article/50b26a601d0ccd1fPharmaRadar360en2026-04-29T06:01:54.000ZBoletín sobre Cosméticos, Biocidas AEMPS y Productos de Cuidado Personal. Enero-marzo 2026https://www.pharmaradar360.com/article/45bb611b8fa0992dPharmaRadar360en2026-04-29T03:47:50.000ZAcross the Codes: Navigating MedTech Compliance Expectations in the Regionhttps://www.pharmaradar360.com/article/1f39c8dc6825a66ePharmaRadar360en2026-04-29T02:00:00.000ZWegovy and Mounjaro for weight loss not fundedhttps://www.pharmaradar360.com/article/71e03b0a0c896669PharmaRadar360en2026-04-29T00:00:00.000ZGSK delivers strong Q1 performance and start to 2026https://www.pharmaradar360.com/article/f1ea0ea596d228b5PharmaRadar360en2026-04-29T00:00:00.000ZGH Research Announces Pricing of $117.5 Million Underwritten Offeringhttps://www.pharmaradar360.com/article/a03a1072e1247680PharmaRadar360en2026-04-29T00:00:00.000ZWhy Pickleball Injuries Are So Commonhttps://www.pharmaradar360.com/article/ac18798dd1f06352PharmaRadar360en2026-04-29T00:00:00.000ZCleveland Clinic Establishes Space Health Centerhttps://www.pharmaradar360.com/article/56765e6acc772634PharmaRadar360en2026-04-29T00:00:00.000ZUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directorshttps://www.pharmaradar360.com/article/a4fe613b475fa968PharmaRadar360en2026-04-29T00:00:00.000ZBausch Health Announces First Quarter 2026 Resultshttps://www.pharmaradar360.com/article/4875a4b5bf7e7b09PharmaRadar360en2026-04-28T18:06:58.000ZWe fact-checked the hype behind the Eledon Pharmaceuticals Type 1 diabetes treatment